PatientsVille.com Logo

DECREASED APPETITE and Ramipril

PatientsVille

DECREASED APPETITE Symptoms and Causes

Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs. It is a serious condition. If you have it, the blood vessels that carry blood from your heart to your lungs become hard and narrow. Your heart has to work harder to pump the blood through. Over time, your heart weakens and cannot do its job and you can develop heart failure.

Symptoms of PH include

  • Shortness of breath during routine activity, such as climbing two flights of stairs
  • Tiredness
  • Chest pain
  • A racing heartbeat
  • Pain on the upper right side of the abdomen
  • Decreased appetite

As PH worsens, you may find it hard to do any physical activities.

There are two main kinds of PH. One runs in families or appears for no known reason. The other kind is related to another condition, usually heart or lung disease.

There is no cure for PH. Treatments can control symptoms. They involve treating the heart or lung disease, medicines, oxygen, and sometimes lung transplantation.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for DECREASED APPETITE

DECREASED APPETITE treatment research studies

Ramipril clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ramipril Side Effects

Renal Failure Acute (252)
Dyspnoea (156)
Angioedema (149)
Hypotension (148)
Dizziness (130)
Cough (125)
Dehydration (107)
Nausea (105)
Hyperkalaemia (104)
Hyponatraemia (97)
Diarrhoea (95)
Confusional State (91)
Syncope (87)
Vomiting (87)
Malaise (85)
Fall (82)
Fatigue (78)
Chest Pain (78)
Headache (77)
Asthenia (75)
Swollen Tongue (65)
Lip Swelling (64)
Blood Pressure Increased (63)
Blood Creatinine Increased (62)
Cardiac Failure (62)
Hypoaesthesia (61)
Pruritus (58)
Palpitations (55)
Renal Failure (55)
Loss Of Consciousness (54)
Hypertension (52)
Haemoglobin Decreased (48)
Atrial Fibrillation (47)
Condition Aggravated (47)
Somnolence (45)
Pain In Extremity (44)
Paraesthesia (43)
Rash (42)
Abdominal Pain (41)
Hyperhidrosis (39)
Overdose (38)
Pneumonia (38)
International Normalised Ratio Increased (38)
Depression (37)
Vision Blurred (36)
Renal Impairment (36)
Lactic Acidosis (36)
Bradycardia (36)
Sepsis (35)
Myalgia (35)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Aside from auto-bruising and some annoying balance problems the ultimate killer was an attack of light-headedness !! Incidentally my Doctor at the time refused to even discuss side effects let alone assist in mitigating !! Needless to say I fir

Can Ramipril ranbaxy cause itchiness and if so, is it best to avoid this medication?

Can I take ciprofloxacin with my medicines for diabetes

Extreme uncontrolled coughing for 6 weeks

Hi i have been on ramipril about 4 years now. but i am also taking amlopdine'simvastatin'tramadol'naproxen'and lansoprazole.which are causing all sorts problems such as extreme muscle pain and stomach pain swollen eyelids swollen throat rashes. inso

I am 48 and have been on rampiril 5mg along with crestor 5mg since the last 8 months. I have been experiencing irritation in my throat, very dry throat and severe cough. at times I suspect this is due to rampiril. I am otherwise fit and have had no

I am taking rampihil 5 mg a day. I have a cough. Blurred vision. Dizzy. And i have now had 3 outbreaks of genital herpes since taking it in mid may 2011. What is your opinion?

I can sympathise with the back pain i have it in between my shoulders and there are times I could cry it hurts so but my GP says its not the meds but it only started when I started taking these tablets I too have found lots of comments on the interne

I get the same dry throat this is a common side effect.

I had very similar symptoms and would even double up with the pain. Would only easy when I vomitted. However, now I do get the gas attacks and bloated feeling, but the body seesm to have got used to it

1st day was hell, had about every side effect in the book. 2nd day was better, side effects decreased greatly 5th day is going well so far- feeling a little 'edgy & apprehensive' but better than the alternative

40mg per dose 3 days a week Nausea and tiredness and fatigue and loss of appetite 30 mg - doing better But has anyone else experienced a sore tender neck with radiating sore ear jaw and headache

Afater taking glifage for 5 months, stopped because of complete lack of appetite and taste, loss of 20 lbs. and thinking process affected.

After 1 day I developed sevre flu-like body aches and total loss of appetite. It was 4 days before I remembered to read the side effect fact sheet and realized what this drug was putting me through. I had shortness of breath wnen I tried to

After a few weeks on Piascledine, knee and back pain decreased considerably with no side effects noted. Not perfect, but much better. I was walking like an old man.

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

After dealing with nausea for days, total lack of appetite I then started with a temp.of 101.5 and it went up to 103. That lasted for 3 days ( my sinuss infection at this point was cleard up, so I stopped taking the meds. NOW, I am experiencing very

After having stilnoct for atleast 6 months, there is occuring of head heaviness,fever, dry mouth,constipation, lack of appetite.

Age 79, sciatic, pain relief with 2 to 3 per day. slight loss of appetite

Am on Klacid, two tablets daily. Experiencing increase in heart rate, Chest pains, Bitter taste in the mouth day and night; also everything tastes bitter, Lack of appetite, stomach ache, abdominal pains,stomach bloated; tired yet anxious. Sleepless n

DECREASED APPETITE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Conditions: Diabetes Type 2;   Diabetic Nephropathy;   Vascular Disease
Interventions: Drug: Ramipril;   Drug: Clopidogrel
Outcome Measures: Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in urine 8-isoprostane-F2 levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Reduction in albumine to creatine ratio after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in ADMA blood levels after treatment with Ramipril;   Increase of Glomerular Filtration Rate (GFR) after combined treatment with Ramipril and clopidogrel and after Ramipril monotherapy;   Change from baseline in carotid intima-media thickness after combined therapy with Ramipril and clopidogrel and after Ramipril monotherapy
2 Recruiting Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Condition: Metabolic Syndrome
Interventions: Drug: Ramipril;   Drug: HCTZ-hydrochlorothiazide;   Drug: Ramipril+HCTZ
Outcome Measure: Changes in Insulin Sensitivity
3 Recruiting Ramipril for the Treatment of Oligospermia
Conditions: Oligospermia;   Teratospermia;   Asthenozoospermia;   Male Infertility
Interventions: Drug: Ramipril;   Drug: Placebo
Outcome Measures: Sperm density in infertile men with documented oligospermia.;   Total Motile Sperm Count(TMSC), total sperm count, sperm motility, and morphology in the ejaculate.;   Pregnancy rate;   Hormonal profile
4 Unknown  Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
Condition: Intermittent Claudicants
Intervention: Drug: Ramipril
Outcome Measures: The primary outcome measure for this trial is the Maximum Walking Distance (MWD). Treadmill exercise test will be used to estimate the maximum distance the participant can walk at a speed of 2.5 km/h with a 10 degree incline.;   Other clinical indicators of lower limb ischaemia: a) Patient Reported Walking Distance (PRWD) b) Treadmill Intermittent Claudication Distance (ICD) c) Ankle Brachial Pressure Index at rest (ABPI- r) and following treadmill testing (ABPI - t);   Quality of life: a) Generic - measured using the SF36, SF8 and EuroQol (EQ5D) instruments b) Disease specific - measured using the VascuQol;   Cardiovascular prognosis using: a) Framingham, PROCAM, QRISK and Manchester charts scoring systems b) B-type Natriuretic Peptide (BNP) and N- terminal prohormone BNP (NT-proBNP) and a Lipid profile ( LDL, HDL, Total Cholesterol, Triglycerides);   Markers of endothelial function and ischaemia reperfusion a) IL6 b) soluble Intercellular Adhesion Molecule-1 (sICAM -1) c) sE selectin d) Urine Albumin Creatinine Ratio ( UACR);   Arterial effects: a) Arterial stiffness by measuring the Pulse Wave Velocity and assessing the effects on the extracellular matrix by measuring Metalloproteinases (MMPs) and Tissue Inhibitor Metalloproteinases (TIMPs). b) Flow mediated vasodilatation;   Health economics (cost effectiveness / utility)
5 Unknown  Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
Conditions: Left Atrial Volume;   Hypertensive Heart Disease;   Antihypertensive Drugs;   Diastolic Function;   Renin Angiotensin System
Interventions: Drug: Ramipril;   Drug: irbesartan
Outcome Measures: left atrial volume;   diastolic function;   systolic and diastolic blood pressure
6 Unknown  Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
Conditions: Hypertension;   Type 2 Diabetes Mellitus;   Microalbuminuria
Interventions: Drug: Ramipril;   Drug: Imidapril
Outcome Measures: Size of the reduction of urinary albumin in 24 hours to the various controls;   1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.
7 Not yet recruiting Aliskiren Study of Safety and Efficacy in Senior Hypertensives
Condition: Hypertension
Interventions: Drug: Aliskiren;   Drug: Amlodipine;   Drug: Ramipril;   Drug: Hydrochlorothiazide
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (MSSBP) to week 8;   Number of patients with serious adverse events and adverse events;   Number of patients with hyperkalemia, hypotension and reduction of estimated glomerular filtration rate (eGFR);   Change from baseline in mean sitting systolic blood pressure (MSSBP) at the end of double blind period;   Percentage of patients achieving blood pressure control;   Percentage of patients with major cardiovascular events;   Number of patients with gastrointestinal tract cancer
8 Unknown  Ramipril Versus Carvedilol in Duchenne and Becker Patients
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Interventions: Drug: carvedilol;   Drug: Ramipril
Outcome Measures: Left ventricular Ejection Fraction, systolic and diastolic left ventricular volumes and LGE (as a quantitative measure) detected by MRI and myocardial Ultrasound Tissue Characterisation data by Echocardiography.;   Prevalence of LGE in DMD and BMD patients,the effects of pharmacological therapy both on LGE evolution and myocardial UTC analysis.
9 Unknown  Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria
Conditions: Hypertension;   Type 2 Diabetes
Interventions: Drug: Ramipril;   Drug: Experimental
Outcome Measures: Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus Ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.;   Average of 24 hours by ABPM, systolic and diastolic blood pressure;   Average daytime, systolic and diastolic blood pressure;   Average night, systolic and diastolic blood pressure
10 Recruiting Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Ramipril;   Drug: placebo to Ramipril
Outcome Measures: Time to next disease level;   Incidence of Adverse Drug Events before progression;   Albuminuria after three years;   Adverse Drug Events over three years
11 Unknown  Telmisartan Versus Ramipril After Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Coronary Disease
Interventions: Drug: TELMISARTAN;   Drug: Ramipril
Outcome Measures: High sensitivity C-Reactive Protein;   Endothelial Progenitor Cells
12 Recruiting Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure
Conditions: Chronic Heart Failure;   Cachexia
Intervention:
Outcome Measures: Pharmacokinetic parameters of bisoprolol and Ramipril;   Body composition;   Cachexia diagnosis;   Renal function
13 Not yet recruiting Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
Condition: Coronary Artery Dissection, Spontaneous
Interventions: Drug: Ramipril;   Drug: rosuvastatin;   Drug: placebo
Outcome Measures: Angina frequency domain of the SAQ;   Acute coronary syndrome or hospitalization for angina
14 Recruiting Sevelamer in Proteinuric CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Sevelamer;   Drug: Ramipril and Irbesartan
Outcome Measures: 24-h urinary protein excretion;   Office blood pressure;   Glomerular Filtration Rate
15 Recruiting Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Conditions: Oxidative Stress;   Endothelial Dysfunction
Interventions: Drug: Ramipril (ACE inhibitor);   Drug: valsartan (ARB);   Drug: Placebo
Outcome Measures: To compare the long term effects of ACE inhibition or angiotensin receptor blockade versus placebo on biomarkers of fibrinolysis, oxidative stress and inflammation in patients with chronic kidney disease undergoing maintenance hemodialysis;   To compare the long term effects of ACE inhibition or AT1 receptor blockade versus placebo on carotid intima-media thickness (IMT) in patients with chronic kidney disease undergoing maintenance hemodialysis;   Track safety endpoints- hyperkalemia, hypotension, nonfatal myocardial infarction, nonfatal stroke, death from cardiac causes, fatal stroke, death due to any cause.
16 Unknown  Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
Condition: Metabolic Syndrome X
Interventions: Drug: Eplerenone;   Drug: Ramipril
Outcome Measures: Secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release;   This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
17 Not yet recruiting Cardiac Energetics and Function in Normal Human Ageing
Conditions: Left Ventricular Function Systolic Dysfunction;   Left Ventricular Function Diastolic Dysfunction;   Ageing
Intervention: Drug: Ramipril
Outcome Measures: Vascular Stiffness;   Left Ventricular Energetics;   Left Ventricular Function;   Effects of ACE inhibitor on left ventricular energetics and function in those subjects aged 40 and over
18 Not yet recruiting Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
Conditions: Type 2 Diabetes Mellitus;   Hypertension
Interventions: Drug: Placebo;   Drug: Sitagliptin;   Drug: Aprepitant
Outcome Measures: Blood pressure;   heart rate;   norepinephrine (NE) concentrations;   Low frequency variability of blood pressureactivity, aldosterone;   glucose;   insulin;   DPP4 activity;   ACE
19 Recruiting Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: Ramipril;   Drug: Placebo
Outcome Measures: At least one relevant symptomatic or asymptomatic atrial fibrillation event;   All relevant cardiovascular event;   Secondary effects of the treatment
20 Recruiting Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.
Condition: Myocardial Infarction
Interventions: Drug: FDC;   Drug: Separately drugs, simvastatin, aspirin and Ramipril
Outcome Measures: Proportion of patients receiving AAS, an ACE inhibitor and a statin among those without contraindications to any of these drugs Adherence to treatment measured by: Morinsky-Green test and Pill accountability.;   Adherence to treatment measured by the Morisky-Green questionnaire;   Treatment adherence measured by: Morisky-Green test: (Good adherence score 16-20) at 1 and 9 months.;   Treatment adherence measured by: Pill counts at 1-4-9 months. (Good adherence 80-110% PC);   Blood Pressure and Lipid Profile (LDL-cholesterol) at 1 and 9 months;   Safety and tolerability: Adverse events and rate of treatment withdrawal.